Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Aug 27 (Reuters) - Drug companies Jazz (JAZZ.O), opens new tab and Hikma (HIK.L), opens new tab must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy ...

Hikma Pharmaceuticals' corporate investment arm Hikma Ventures has launched a $30 million digital health fund in Jordan, focusing on therapeutic and diagnostic start-ups. The company's roots are ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) jumped on Thursday after the company raised its full-year guidance ...

Hikma Pharmaceuticals PLC HIK shares inched up 0.88% to £19.53 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

Hikma Pharmaceuticals Plc (HKMPF) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia ...

Hikma Pharmaceuticals PLC HIK shares inched up 0.82% to £19.77 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.35% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...